Table 1.
First author | Year | Country | Inclusion periods | Gender | Inclusion age | AML sourcea | Controls sourcea | Matching criteria | Adjusted ORb | No. AML | No. controls | Exposurec | Quality score (/9)d |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Flodin U33 | 1986 | Sweden | 1977–1982 | M/F | 20–70 | Multicentric | Population | Age, gender, residency | No | 59 | 354 | SAQ | 4 |
Richardson S34 | 1992 | France | 1984–1988 | M/F | > 30 | Multicentric | Hospital | Age, gender, ethnicity, residency | Yes | 154 | 513 | PTP | 8 |
Crane MM35 | 1992 | USA | 1982–1983 | M/F | > 18 | Multicentric | Hospital | Age, gender, ethnicity, year of inclusion | No | 60 | 60 | PTP | 7 |
Ciccone G36 | 1993 | Italy | 1989–1990 | M/F | 15–74 | Monocentric | Hospital and population | Age, gender | Yes | 50 | 246 | PTP | 6 |
Mele A37 | 1994 | Italy | 1986–1990 | M/F | > 15 | Multicentric | Hospital | NS | Yes | 252 | 1,161 | PTP | 4 |
Albin M38 | 2000 | Sweden | 1976–1993 | M/F | > 20 | Multicentric | Population | Age, gender, residency | No | 372 | 351 | PTP | 6 |
Lazarov D39 | 2000 | UK, Yugoslavia | 1986–1994 | M/F | > 18 | Multicentric | Hospital | Age, gender, year of inclusion | No | 98 | 196 | PTP | 7 |
Adegoke OJ40 | 2003 | China | 1987–1989 | M/F | > 15 | Multicentric | Population | Age, gender | Yes | 236 | 502 | PTP | 6 |
Terry PD41 | 2005 | USA, Canada | 1986–1989 | M/F | 17–79 | Multicentric | Population | Age, gender, ethnicity, residency | Yes | 599 | 607 | PTP | 6 |
Kaufman DW42 | 2009 | Thailand | 1997–2003 | M/F | > 18 | Monocentric | Hospital | Age, gender, residency | Yes | 87 | 756 | PTP | 7 |
Wong O43 | 2010 | China | 2003–2007 | M/F | > 18 | Multicentric | Hospital | Age, gender, hospital | No | 722 | 1,444 | PTP | 8 |
Strom SS44 | 2012 | USA | 2003–2007 | M/F | 18–80 | Monocentric | Population | Age, gender, ethnicity, residency | No | 638 | 636 | PTP | 8 |
Parodi S45 | 2017 | Italy | 1990–1993 | M/F | 20–74 | Multicentric | Population | Age, gender | No | 223 | 1,774 | PTP | 7 |
Poynter JN46 | 2017 | USA | 2005–2010 | M/F | 20–79 | Multicentric | Population | Age | Yes | 405 | 1,348 | SAQ | 6 |
aAcute myeloid leukemia (AML) patients and controls source are described in Table S3; bAdjustment variables are fully described in Table S6; cPesticide exposure methods are fully described in Table S2; dQuality score was evaluated with the Newcastle–Ottawa scale for case–control studies (Table S4). NS: not specified; PTP: person-to-person interview; SAQ: self-administered questionnaire; OR: odds ratio.